HERCEPTIN (trastuzumab) Patient Assistance Program
Don’t let the high cost of brand specialty HER2-targeted therapy stand between you and the treatment you need. We help eligible patients access Herceptin (trastuzumab) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Herceptin (trastuzumab) is FDA-approved for HER2-overexpressing breast cancer (early stage adjuvant and metastatic) and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. It is given as an IV infusion (or as Herceptin Hylecta with subcutaneous administration).
- Without assistance, Herceptin costs commonly run $4,000–$8,000+ per IV infusion, with monthly totals typically $5,000–$10,000+ depending on regimen and body weight. A full year of adjuvant therapy commonly costs $80,000–$120,000.
- Through AffordMyPrescriptions, qualifying patients can access Herceptin coverage for a flat $69.95 per month — our advocacy team manages the entire enrollment, infusions, and renewal process.
- Multiple FDA-approved biosimilars to Herceptin (Ogivri, Herzuma, Ontruzant, Trazimera, Kanjinti) are available at significantly lower cost — substitution depends on your oncology team and infusion site.
What Is Herceptin Prescription Assistance Program?
The Herceptin Prescription Assistance Program is a manufacturer-sponsored initiative that provides Herceptin infusions at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HER2+ cancer patients who are uninsured or underinsured, as well as Medicare beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, HER2 testing documentation, prior-authorization documentation, infusion scheduling, cardiac monitoring schedules, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing infusion-schedule coordination and annual re-certification — so you focus on your treatment, not paperwork.
Pharmacy Price Comparison
- Without assistance, Herceptin infusions cost roughly $4,000–$8,000+ each. Multiple biosimilars are available at lower cost. A Patient Assistance Program is the meaningful path for brand pricing — if you qualify:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Per IV infusion (brand) | ~$6,500.00 | Save ~$6,430/dose |
| Per IV infusion (biosimilar) | ~$3,800.00 | Save ~$3,730/dose |
| Monthly cost (typical) | ~$8,000+ | Save ~$7,930/mor |
| Annual adjuvant therapy | ~$100,000+ | Save ~$99,000+/yr |
| Combo with Perjeta (cycle) | Add’l cost | Coordinated by us |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Herceptin Prescription Program?
The Patient Assistance Program is free to apply for and provides Herceptin infusions at little or no medication cost if approved. But the process involves detailed applications, oncology-team coordination, HER2 testing documentation, infusion scheduling, cardiac monitoring (echocardiograms or MUGA scans), and ongoing renewal management. Our $69.95/month service covers full advocacy. With multiple Herceptin biosimilars available at significantly lower cost, we’ll guide you to the most cost-effective path.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Herceptin:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $4,000–$8,000+ per infusion per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Herceptin assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Herceptin Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Herceptin:
Herceptin (trastuzumab) is an intravenous (IV) HER2-targeted monoclonal antibody used to treat HER2-overexpressing breast cancer (in both early-stage adjuvant and metastatic settings) and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Eligibility requires confirmed HER2 overexpression on tumor testing.
How Herceptin Works:
Herceptin is a monoclonal antibody designed to target HER2, a growth factor receptor that drives the rapid proliferation of certain breast and gastric cancers. By binding to these receptors, the medication blocks growth signals and flags the cancer cells for destruction by the body’s immune system. When used alongside chemotherapy, it has significantly improved cure rates for early-stage HER2-positive breast cancers.
Form and use:
This medication is typically administered as an IV infusion in a clinical setting, with a weight-based dosage schedule that can be weekly or every three weeks. A subcutaneous version, Herceptin Hylecta, is also available for specific uses. The duration of treatment varies by the stage of the disease, often lasting 12 months for early breast cancer or continuing until disease progression in metastatic cases.
Generic availability:
While a traditional generic does not exist, several FDA-approved biosimilars for Herceptin (trastuzumab) are available in the U.S., such as Kanjinti, Trazimera, and Ogivri. These biosimilars offer a more cost-effective alternative to the brand-name drug. The choice to use a biosimilar over the brand depends on your medical team’s protocol, the facility’s contracts, and your specific insurance coverage.
Warnings:
Herceptin includes boxed warnings for serious risks such as cardiomyopathy (heart muscle weakness), pulmonary toxicity, and infusion reactions. Because of the risk to the heart, patients must have their cardiac function monitored via echocardiograms or MUGA scans before and during treatment. Patients should immediately report any new symptoms like shortness of breath, chest pain, or swelling to their oncology team.
FAQ (Frequently Asked Questions)
How Much Does Herceptin Cost Without Insurance?
Per-infusion costs commonly run $4,000–$8,000+ for brand Herceptin. Biosimilars are typically 30–40% cheaper. A full year of adjuvant therapy commonly costs $80,000–$120,000. Through AffordMyPrescriptions, qualifying patients receive Herceptin (or biosimilar) at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Are Biosimilars To Herceptin The Same Medicine?
Biosimilars (Ogivri, Herzuma, Ontruzant, Trazimera, Kanjinti) are FDA-approved as highly similar to and clinically equivalent to brand Herceptin (trastuzumab). They contain the same active ingredient and produce the same clinical results. Whether your infusion is filled as brand or biosimilar depends on your oncology team and infusion site — for many patients, the biosimilar at lower cost is the right path.
How Is HER2 Status Confirmed?
HER2 status is confirmed by tumor testing — typically immunohistochemistry (IHC) staining and/or fluorescence in-situ hybridization (FISH). Herceptin is approved only for cancers that have been confirmed HER2-overexpressing or HER2-amplified on these tests
Why Is Cardiac Monitoring Required?
Herceptin can cause cardiomyopathy (weakening of the heart muscle). Cardiac function (left ventricular ejection fraction, or LVEF) is assessed at baseline and at regular intervals during therapy with echocardiogram or MUGA scan. The risk is higher when Herceptin is given with anthracycline chemotherapy. Most cases are reversible if caught early and Herceptin is paused or stopped.
How Long Will I Need Herceptin?
For early-stage breast cancer adjuvant therapy, Herceptin is typically given for 12 months. For metastatic disease, it is given until progression or unacceptable toxicity. Your oncology team will follow imaging and biomarkers to determine the right duration for your situation.
What If My Application Is Denied?
If your initial application is denied, we explore alternatives — switching to a Herceptin biosimilar at significantly lower cost, the manufacturer’s copay assistance program if you have commercial insurance, independent foundations such as the PAN Foundation, HealthWell Foundation, Susan G. Komen, or Living Beyond Breast Cancer, or asking your oncology team whether a different HER2-targeted therapy would be appropriate. If we cannot find a path, you will not be charged our service fee.
Take Control of Your Medication Costs
If you are struggling with the high cost of Herceptin, our team may be able to help you access assistance programs — or guide you to the cheaper biosimilar path if it is the better fit. Check your eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.